M&A M&A
Dr Lal PathLabs acquires remaining 30% stake in diagnostics services provider Centrapath Labs
Source Centrapath Labs (opens in a new tab)Business Line (opens in a new tab)BSE Announcement (opens in a new tab)
Publicly-listed Dr Lal PathLabs has acquired the remaining 30% equity stake in Indore, Madhya Pradesh-based Centrapath Labs , at a price of INR 1,608.35 per share. Post transaction, Centrapath has become a wholly owned subsidiary of PathLabs Unifiers, which is a subsidiary of Dr Lal PathLabs.Founded in 2019, Centrapath Labs provides healthcare and diagnostic services. The firm reported a turnover of INR 20.5 crore in FY26, INR 23.7 crore in FY25, and INR 20.8 crore in FY24.